Essential atlas of heart diseases
著者
書誌事項
Essential atlas of heart diseases
McGraw-Hill, c2001
2nd ed
大学図書館所蔵 全5件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
"Developed by Current Medicine, Inc., Philadelphia"
内容説明・目次
内容説明
A full-color atlas designed to provide all health care professionals with a detailed pictorial presentation of cardiovascular diseases and their treatment. Updated throughout, the Second Edition highlights important points in summary boxes, and features information on new drugs and clinical trials.
目次
- Specific Changes as Described by Current Science
- Chapter 1: New figure on the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial. Added two new figures, Lipid Concentrations According to Year of Study and Treatment Group
- Kaplan-Meier Estimates of the Incidence of Death from Coronary Heart Disease and Nonfatal Myocardial Infarction in the Gemfibrozil and Placebo Groups. Chapter 2: Figure 2-15 replaced with new figure showing the systematic overview of ACE inhibitor trials post-myocardial infarction. Figure 2-18 replaced with figure listing the antithrombotic agents in acute coronary systems. Figure 2-19 replaced with figure showing the systematic overview of aspirin vs heparin clinical trials. Figure 2-28 replaced by new table on characteristics of thrombolytic agents. New figure added showing results of the Gusto III trial and Assent II trial. Figure 2-43 replaced with figure showing systematic overview of various glycoprotein Iib/IIIa inhibitors vs placebo trials in acute coronary syndromes. New figure showing outcomes of before and after percutaneous intervention in patients treated with glycoprotein Iib/IIIa inhibitors. New figure comparing direct PTCA and thrombolysis. Figure 2-51 replaced by the survivial curves from the Shock Trial. Chapter 4: New sections "Molecular and Cellular Mechanisms of Myocardial Remodeling," "Matrix remodeling," and "Inflammatory Cytokines" Chapter 7: Revise figure 7-51 to include angiotensin-receptor blockers. Added info on the Syst-Eur study, losartan, eprosartan, and dual metalloproteinase and vasopeptidase inhibitors. Chapter 8: New tables "Indications for Surgery for Severe for AS" and "Valve Selection for an Individual Patient" Chapter 9: See author's letter in your mailbox. Dr. Freedom determined that this chapter did not need updating
- Braunwald approved. Chapter 10: New figures on Manifestations of Upper-airway Closure, cardiac myxoma.
「Nielsen BookData」 より